Zheng Y, Shi J
Discov Oncol. 2025; 16(1):249.
PMID: 40014231
PMC: 11868007.
DOI: 10.1007/s12672-025-01867-y.
Shah S, Nag A, Sachithanandam S, Lucke-Wold B
Biomedicines. 2025; 12(12.
PMID: 39767571
PMC: 11727522.
DOI: 10.3390/biomedicines12122664.
Luo D, Luo A, Hu S, Zhao H, Yao X, Li D
Transl Cancer Res. 2024; 13(11):5883-5897.
PMID: 39697739
PMC: 11651736.
DOI: 10.21037/tcr-23-2077.
Can W, Yan W, Luo H, Xin Z, Yan L, Deqing L
Heliyon. 2024; 10(17):e37012.
PMID: 39319137
PMC: 11419897.
DOI: 10.1016/j.heliyon.2024.e37012.
Zheng F, Zhang L, Chen H, Zang Y, Chen X, Li Y
J Radiat Res. 2024; 65(3):350-359.
PMID: 38650477
PMC: 11115443.
DOI: 10.1093/jrr/rrae007.
Exosomal DNA: Role in Reflecting Tumor Genetic Heterogeneity, Diagnosis, and Disease Monitoring.
Xiang Z, Xie Q, Yu Z
Cancers (Basel). 2024; 16(1).
PMID: 38201485
PMC: 10778000.
DOI: 10.3390/cancers16010057.
Precision medicine advancements in glioblastoma: A systematic review.
Iyer K, Saini S, Bhadra S, Kulavi S, Bandyopadhyay J
Biomedicine (Taipei). 2023; 13(2):1-13.
PMID: 37937301
PMC: 10627207.
DOI: 10.37796/2211-8039.1403.
Epigenetic Activation of TUSC3 Sensitizes Glioblastoma to Temozolomide Independent of MGMT Promoter Methylation Status.
Wu Q, Berglund A, Macaulay R, Etame A
Int J Mol Sci. 2023; 24(20).
PMID: 37894860
PMC: 10606804.
DOI: 10.3390/ijms242015179.
Cell-Free miRNAs as Non-Invasive Biomarkers in Brain Tumors.
Beylerli O, Encarnacion Ramirez M, Shumadalova A, Ilyasova T, Zemlyanskiy M, Beilerli A
Diagnostics (Basel). 2023; 13(18).
PMID: 37761255
PMC: 10529040.
DOI: 10.3390/diagnostics13182888.
The dark side of mRNA translation and the translation machinery in glioblastoma.
Montiel-Davalos A, Ayala Y, Hernandez G
Front Cell Dev Biol. 2023; 11:1086964.
PMID: 36994107
PMC: 10042294.
DOI: 10.3389/fcell.2023.1086964.
Medulloblastoma and the DNA Damage Response.
McSwain L, Parwani K, Shahab S, Hambardzumyan D, MacDonald T, Spangle J
Front Oncol. 2022; 12:903830.
PMID: 35747808
PMC: 9209741.
DOI: 10.3389/fonc.2022.903830.
Study on the mechanism of let-7a-5p in regulating the proliferation in cervical cancer cells.
Chen Z, Qiu J, Gao Y, Lu Q, Lin Y, Shi H
Clin Transl Oncol. 2022; 24(8):1631-1642.
PMID: 35303268
DOI: 10.1007/s12094-022-02810-1.
Radiomics Analysis Based on Magnetic Resonance Imaging for Preoperative Overall Survival Prediction in Isocitrate Dehydrogenase Wild-Type Glioblastoma.
Wang S, Xiao F, Sun W, Yang C, Ma C, Huang Y
Front Neurosci. 2022; 15:791776.
PMID: 35153659
PMC: 8833841.
DOI: 10.3389/fnins.2021.791776.
Bevacizumab plus irinotecan with or without gamma knife radiosurgery after failure of concurrent chemo-radiotherapy for high-grade glioma.
Lee Y, Jung H, Lee M, Choi J, Kong D, Seol H
J Neurooncol. 2022; 156(3):541-549.
PMID: 35094201
DOI: 10.1007/s11060-021-03930-4.
Exploring the efficacy of tumor electric field therapy against glioblastoma: An in vivo and in vitro study.
Wu H, Yang L, Liu H, Zhou D, Chen D, Zheng X
CNS Neurosci Ther. 2021; 27(12):1587-1604.
PMID: 34710276
PMC: 8611775.
DOI: 10.1111/cns.13750.
Against the Resilience of High-Grade Gliomas: The Immunotherapeutic Approach (Part I).
Lucifero A, Luzzi S
Brain Sci. 2021; 11(3).
PMID: 33803885
PMC: 8003180.
DOI: 10.3390/brainsci11030386.
Role of Tumor-Derived Extracellular Vesicles in Glioblastoma.
Chen Y, Jin Y, Wu N
Cells. 2021; 10(3).
PMID: 33670924
PMC: 7997231.
DOI: 10.3390/cells10030512.
Tumor recurrence or treatment-related changes following chemoradiation in patients with glioblastoma: does pathology predict outcomes?.
Patrizz A, Dono A, Zhu P, Tandon N, Ballester L, Esquenazi Y
J Neurooncol. 2021; 152(1):163-172.
PMID: 33481149
PMC: 8394701.
DOI: 10.1007/s11060-020-03690-7.
Tim-3 Expression and MGMT Methylation Status Association With Survival in Glioblastoma.
Zhang J, Sai K, Wang X, Ye S, Liang L, Zhou Y
Front Pharmacol. 2020; 11:584652.
PMID: 33041828
PMC: 7522578.
DOI: 10.3389/fphar.2020.584652.
